The American Gastroenterological Association released guidelines for hepatocellular carcinoma treatment Feb. 22.
Four recommendations from the AGA:
1. Systemic therapies are only recommended for those in stage C with preserved liver function. Atezolizumab and bevacizumab are recommended for first-line treatments rather than sorafenib.
2. Those in stage 0 and A who are also eligible for ablation, resection or transplant should receive curative surgery rather than systemic therapies.
3. Transarterial chemoembolization should be the first-line treatment for those in stage B.
4. Stage D patients should not receive systemic therapies. Instead, they should receive a transplant or best supportive care.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
